CDC14B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16282346	0.54	9/20
SCHEMBL21343390	0.52	9/20
SCHEMBL21862219	0.51	4/20
SCHEMBL1926670	0.50	4/20
SCHEMBL20205417	0.38	4/20
SCHEMBL4552061	0.36	4/20
SCHEMBL3745971	0.52	3/20
SCHEMBL18382951	0.52	3/20
SCHEMBL22884603	0.52	3/20
SCHEMBL18382954	0.50	3/20
SCHEMBL20462447	0.50	3/20
SCHEMBL22891427	0.50	3/20
SCHEMBL25907810	0.50	3/20
SCHEMBL23752182	0.45	3/20
SCHEMBL22155881	0.43	3/20
SCHEMBL23504475	0.40	3/20
SCHEMBL23504530	0.40	3/20
SCHEMBL23504531	0.40	3/20
SCHEMBL23504594	0.40	3/20
SCHEMBL23504600	0.40	3/20

Clinical trials — most relevant to CDC14B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer	PHASE1/PHASE2	UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Somatic Mosaicism in Twins Discordant for Childhood Cancer	nan	RECRUITING
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study	nan	ACTIVE_NOT_RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome	nan	ACTIVE_NOT_RECRUITING
Dissect Assembly Rules of SPET12 Complex in the Mammalian Sperm	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique	nan	UNKNOWN
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC14B binder may also engage these)

Protein	Name	Similarity
Q59NH8	—	1.000	Q59NH8 →
Q6GQT0	—	1.000	Q6GQT0 →
A4D256	—	0.999	A4D256 →
CDC14A	Dual specificity protein phosphatase CDC14A	0.997	landscape →
A6N3Q4	—	0.994	A6N3Q4 →
Q6PFY9	—	0.994	Q6PFY9 →
Q9P7H1	—	0.994	Q9P7H1 →
A0A0R4IVA4	—	0.993	A0A0R4IVA4 →
Q9TYU5	—	0.992	Q9TYU5 →
Q9VR59	—	0.992	Q9VR59 →
O01991	—	0.992	O01991 →
O76373	—	0.990	O76373 →
Q6CKE9	—	0.989	Q6CKE9 →
Q20402	—	0.989	Q20402 →
Q09488	—	0.988	Q09488 →
Q9D1P2	—	0.988	Q9D1P2 →
PDE8B	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B	0.988	landscape →
O43001	—	0.988	O43001 →
Q05733	—	0.988	Q05733 →
Q9VM91	—	0.988	Q9VM91 →
P40421	—	0.988	P40421 →
Q61T02	—	0.988	Q61T02 →
V6CIV8	—	0.988	V6CIV8 →
Q960X4	—	0.988	Q960X4 →
Q8LI34	—	0.988	Q8LI34 →
Q9VM92	—	0.987	Q9VM92 →
Q60L58	—	0.987	Q60L58 →
P30645	—	0.987	P30645 →
Q5SVQ0	—	0.987	Q5SVQ0 →
Q10003	—	0.987	Q10003 →